Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Second Stage Study of Therapeutic HBV Vaccine εPA-44 in Chronic Hepatitis B
NCT02862106Phase 2Completed
- Sponsor
- Chongqing Jiachen Biotechnology Ltd.
- Start
- Sep 2010
- Primary completion
- Mar 2013
- Modality
- Vaccines & Immunotherapeutics, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label trial of therapeutic HBV vaccine in Chronic Hepatitis B (CHB) (6 arms), sponsored by Chongqing Jiachen Biotechnology Ltd. Primary endpoint: Proportion of Patients About HBeAg / Anti-HBe Seroconversion at the End of the Follow-up Period at 144 weeks. Started Sep 2010; status: completed.
02
Drugs
therapeutic HBV vaccine
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT02862106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02862106.